Sign In
Last checked at 
27 Jun 2025 14:38
27 June 2025
Solvonis Therapeutics plc
("Solvonis" or the "Company")
AGM statement and strategic update
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that all resolutions proposed at its Annual General Meeting ("AGM") held earlier today were duly passed. A summary of the resolutions is provided at the end of this announcement.
This year's AGM marks a significant milestone in the Company's growth trajectory. Following the successful completion of the acquisition of Awakn Life Sciences on 28 May 2025, Solvonis has rapidly established itself as a leading European innovator in the development of precision neuropsychiatric therapeutics.
The combined company now benefits from a high-quality pipeline of preclinical and clinical-stage assets targeting alcohol use disorder, post-traumatic stress disorder, and other complex neuropsychiatric conditions. These programmes, including lead candidate SVN-001, are underpinned by translational science, real-world evidence, and a regulatory strategy aligned with expedited pathways in key jurisdictions.
Integration activities are progressing in line with plan, with a focus on operational efficiency, disciplined capital deployment, and preparing lead programmes for Phase 3 readiness and partnering opportunities. Solvonis continues to advance a virtual biotech model, supported by a lean team and an expanding network of expert collaborators and CROs.
Anthony Tennyson, CEO of Solvonis Therapeutics, commented: "Today's AGM reflects strong shareholder support for our vision and execution. With the acquisition of Awakn now complete, we are strategically positioned to lead in transforming the treatment landscape for substance use and treatment-resistant mental health disorders across Europe and beyond. We are focused on delivering value through rigorous development, targeted commercial strategy, and partnerships that extend our reach and impact."
The Board remains committed to building a capital-efficient, data-driven, and licensing-led business capable of delivering meaningful therapeutic advances and long-term value creation.
Further updates on programme progress and strategic initiatives will be provided in due course.
As noted, all resolutions proposed at the meeting were passed. The results of voting on each resolution are summarised below:
Resolution | Votes for | For % | Votes against | Against % | Votes total | Votes withheld |
Resolution 1 | 600,321,074 | 99.90% | 572,816 | 0.10% | 600,893,890 | 2,000 |
Resolution 2 | 565,318,574 | 99.90% | 572,816 | 0.10% | 565,891,390 | 35,004,500 |
Resolution 3 | 599,379,529 | 99.75% | 1,514,361 | 0.25% | 600,893,890 | 2,000 |
Resolution 4 | 564,851,874 | 99.82% | 1,039,516 | 0.18% | 565,891,390 | 35,004,500 |
Resolution 5 | 564,851,874 | 99.82% | 1,039,516 | 0.18% | 565,891,390 | 35,004,500 |
Resolution 6 | 599,846,229 | 99.83% | 1,047,661 | 0.17% | 600,893,890 | 2,000 |
Resolution 7 | 564,377,029 | 93.92% | 36,516,861 | 6.08% | 600,893,890 | 2,000 |
Resolution 8 | 600,321,074 | 99.90% | 572,816 | 0.10% | 600,893,890 | 2,000 |
Notes:
1) Resolutions 1 to 6 were passed as ordinary resolutions. Resolution 7 and 8 were passed as special resolutions.
2) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" any of the resolutions.
3) As at the date of the GM, the Company's issued share capital consisted of 5,908,770,690 ordinary shares of £0.001 each.
Enquiries:Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive Directoranthony@solvonis.comAllenby Capital Limited (Financial Adviser and Joint Broker)Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)Guy McDougall (Sales & Corporate Broking)+44 (0) 20 3328 5656Singer Capital Markets (Joint Broker)Phil Davies+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.
The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.
Follow the stocks
